zealand pharma glp 1 Obesity drug from shows potential in early trial Zealand Pharma Abandons Dapiglutide, Shifts
Description
What do GLP-1 medication consumption data actually measure
Among 169,649 patients with MASLD, GLP-1 receptor agonist initiation was linked to significantly lower probability of incident cirrhosis [adjusted hazard ratio (aHR): 0.86, 95%CI: 0.80-0.93], hepatic decompensation (aHR: 0.77, 95%CI: 0.65-0.90), and hepatocellular carcinoma (HCC) (aHR: 0.79, 95%CI: 0.68-0.92) over a median follow-up of 3.5 years compared to non-users
In contrast to SCFA, bile acids are produced by the host
This option is especially beneficial for those with specific allergies or sensitivities to certain ingredients in commercially available GLP-1 medications
This non-GMO Akkermansia Muciniphila Probiotic Supplement supports gut health for both women and men
